FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  TAGLICH ROBERT
2. Date of Event Requiring Statement (Month/Day/Year)
04/12/2017
3. Issuer Name and Ticker or Trading Symbol
Icagen, Inc. [NONE]
(Last)
(First)
(Middle)
C/O ICAGEN, INC. 4222 EMPEROR BLVD,, SUITE 350, RESEARCH TRIANGLE PARK
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

DURHAM,, NC 27703
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, $0.001 par value 336,410 (1)
D
 
Common Stock, $0.001 par value 16,000 (2)
I
See footnote (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant 04/12/2017 04/11/2022 Common Stock 75,000 (3) $ 3.5 D (3)  
Warrant 04/13/2017 04/12/2022 Common Stock 7,500 (4) $ 3.5 D (4)  
Warrant 06/30/2016 06/29/2021 Common Stock 36,405 (5) $ 3.5 D  
Warrant 01/07/2015 01/07/2020 Common Stock 70,091 $ 3.5 D  
Warrant 01/07/2015 01/07/2020 Common Stock 71,429 (6) $ 3.5 D (6)  
Warrant 06/30/2013 06/30/2020 Common Stock 33,928 $ 3.85 D  
Warrant 04/23/2013 04/23/2020 Common Stock 10,000 $ 3.5 D  
Warrant 04/19/2013 04/19/2020 Common Stock 20,677 $ 3.5 D  
Warrant 12/18/2012 12/18/2017 Common Stock 30,000 $ 4.2 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
TAGLICH ROBERT
C/O ICAGEN, INC. 4222 EMPEROR BLVD,
SUITE 350, RESEARCH TRIANGLE PARK
DURHAM,, NC 27703
    X    

Signatures

/s/ Robert Taglich 04/14/2017
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Of the 336,410 shares of common stock, par value, $0.001 per share ("Common Stock"), of Icagen, Inc. (the "Company"), 285,714 shares are held in the reporting person's individual retirement account.
(2) Shares are held in four custodial accounts for the benefit of the reporting person's minor children.
(3) These warrants were issued to the reporting person by the Company in a private placement offering (the "2017 Offering") of units (the "Units" and each a "Unit") with each Unit sold at a price of $10,000 per Unit and each Unit consisting of (i) a note in the principal amount of $10,000, and (ii) a five year warrant to acquire 1,500 shares of the Common Stock at an exercise price of $3.50 per share. Each warrant is exercisable for one share of Common Stock. The reporting person has the right to exchange these warrants for a like number of warrants to be issued to the lender in the Company's next debt financing.
(4) The Company retained Taglich Brothers, Inc. as the exclusive placement agent for the 2017 Offering (the "2017 Placement Agent"). As compensation for the Placement Agent's services in the Offering, the Company (i) paid the Placement Agent a cash commission on the gross proceeds raised (excluding amounts invested by the Company's Chairman of the Board) and (ii) issued the Placement Agent the same warrant that the investors received in the Offering exercisable for an aggregate amount of 25,000 shares of Common Stock at an exercise price of $3.50 per share (2,500 shares of Common Stock for each $100,000 in principal amount of notes sold, excluding notes sold to the Chairman of the Board). The reporting person was issued these warrants as the designee of the Placement Agent. The reporting person has the right to exchange these warrants, which designated to him by the Placement Agent, for a like number of warrants to be issued to the lender in the Company's next debt financing.
(5) Includes warrants to purchase 6,405 shares of the common stock issued to the reporting person as the designee of the placement agent in the issuer's 2016 bridge financing.
(6) Held in the reporting person's individual retirement account.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.